ICON Launches Medical Device & Diagnostics Research Group
09 Março 2015 - 8:30AM
Business Wire
Dedicated Services to Support Medical Device
Manufacturers throughout the Product Lifecycle
ICON plc, (NASDAQ: ICLR) a global provider of drug
development solutions and services to the pharmaceutical,
biotechnology and medical device industries, today announced the
launch of a new Medical Device & Diagnostics Research group
focused on the unique requirements of the medical device and
diagnostics industry
The new group combines the medical and regulatory device and
diagnostic expertise of Aptiv Solutions, which ICON acquired in
2014, with ICON’s global clinical development and
commercialisations solutions. Device and diagnostic manufacturers
can now benefit from an expanded suite of services that support the
full product lifecycle, including global clinical trial execution,
health economics and pricing and market access solutions.
“The device and diagnostic development model can differ
significantly from that of pharmaceutical companies, both in
complexity and time to market,” commented Elizabeth Thiele,
President, ICON Commercialisation & Outcomes. “Operating under
specific medical device SOPs and ISO certification, our new Medical
Device & Diagnostics Research team has the expertise and
flexibility to help manufacturers take time and cost from their
development programmes and maximise the value of their
products.”
ICON’s Medical Device & Diagnostics Research group will be
led by Vicki Anastasi, Vice President, Medical Device &
Diagnostic Research, who has over 20 years of medical device and
diagnostics experience. The group is comprised of a team of
dedicated project managers and clinical operations professionals as
well as regulatory and strategic consultants.
About ICON plc
ICON plc is a global provider of drug development solutions and
services to the pharmaceutical, biotechnology and medical device
industries. The company specialises in the strategic development,
management and analysis of programs that support clinical
development - from compound selection to Phase I-IV clinical
studies. With headquarters in Dublin, Ireland, ICON currently,
operates from 83 locations in 38 countries and has approximately
10,600 employees.
Further information is available at www.iconplc.com.
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
ICON/ICLR-G
ICON Rebecca PowerWeber ShandwickTel: +44 (0) 207 067
0866Email: RPower@webershandwick.com
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024